Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes-Reference-Cited by-同舟云学术

Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes

Published:2022-09-27 Issue:10 Volume:1 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Claggett Brian Lee¹,McCaw Zachary R.²,Tian Lu³,McMurray John J. V.⁴,Jhund Pardeep S.⁴,Uno Hajime⁵,Pfeffer Marc A.¹,Solomon Scott D.¹,Wei Lee-Jen⁶

Affiliation:

1. Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston

2. Insitro, South San Francisco

3. Department of Biomedical Data Science, Stanford University, Stanford, CA

4. British Heart Foundation Glasgow Cardiovascular Research Center, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland

5. Department of Data Science, Dana-Farber Cancer Institute, Boston

6. Harvard T.H. Chan School of Public Health, Boston

Publisher

Massachusetts Medical Society

Reference30 articles.

1. Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms

2. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved

3. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

4. Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials

5. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 15th Annual University of Pennsylvania conference on statistical issues in clinical trial/advances in time to event analyses in clinical trials (morning panel discussion);Clinical Trials;2024-08-30

2. Analysis of composite time-to-event endpoints in cardiovascular outcome trials;Clinical Trials;2024-08-08

3. The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development;JACC: Basic to Translational Science;2024-08

4. Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings;Advances in Therapy;2024-06-04

5. Simulation‐based sample size calculations of marginal proportional means models for recurrent events with competing risks;Pharmaceutical Statistics;2024-03-20